Does Rallies show Form 4 insider transactions for PCRX?

Yes. Rallies tracks PCRX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is PCRX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for PCRX. It does not provide personalized investment advice.

PCRX (Pacira BioSciences, Inc. Common Stock) Stock Analysis - Insider Trades

Pacira BioSciences, Inc. Common Stock (PCRX) is a publicly traded Healthcare sector company. As of May 20, 2026, PCRX trades at $22.23 with a market cap of $882.97M and a P/E ratio of 140.38. PCRX moved -1.70% today. Year to date, PCRX is -8.79%; over the trailing twelve months it is -14.68%. Its 52-week range spans $13.89 to $27.64. Analyst consensus is buy with an average price target of $28.40. Rallies surfaces PCRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading PCRX stock inside the company?

Recent PCRX insider activity includes Cross Shawn sold 12.94K, Cross Shawn sold 1.50K, Cross Shawn sold 2.85K, Cross Shawn sold 7.71K, and SLONIN JONATHAN sold 3.26K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

PCRX Key Metrics

Key financial metrics for PCRX
Metric	Value
Price	$22.23
Market Cap	$882.97M
P/E Ratio	140.38
EPS	$0.16
Dividend Yield	0.00%
52-Week High	$27.64
52-Week Low	$13.89
Volume	64.84K
Avg Volume	0
Revenue (TTM)	$726.41M
Net Income	$7.03M
Gross Margin	79.39%

Recent PCRX Insider Trades

Cross Shawn sold 12.94K (~$325.60K) on Apr 23, 2026.
Cross Shawn sold 1.50K (~$37.52K) on Apr 22, 2026.
Cross Shawn sold 2.85K (~$71.15K) on Apr 21, 2026.
Cross Shawn sold 7.71K (~$193.93K) on Apr 20, 2026.
SLONIN JONATHAN sold 3.26K (~$74.42K) on Mar 17, 2026.

Latest PCRX News

Pacira Unveils $200M Buyback, 2025 Revenue Hits $726.4M with 79.4% Margin — May 20, 2026
Pacira Seeks Support for Three Nominees to Execute 5x30 Growth Strategy at June 9 Meeting — May 12, 2026
Pacira Seeks Proxy Support After Q1 Sales Total $176.3M, Stock Up 30% — May 5, 2026
Pacira BioSciences Plans $30M Q2 R&D Ramp and H2 SG&A Cuts — May 1, 2026
Pacira BioSciences $171.8M Q1 Revenue Forecast; PharmaCorp RX to Acquire 8 Pharmacies — Apr 30, 2026

PCRX Analyst Consensus

6 analysts cover PCRX: 0 strong buy, 3 buy, 2 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $28.40.

Common questions about PCRX

Who is trading PCRX stock inside the company?: Recent PCRX insider activity includes Cross Shawn sold 12.94K, Cross Shawn sold 1.50K, Cross Shawn sold 2.85K, Cross Shawn sold 7.71K, and SLONIN JONATHAN sold 3.26K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for PCRX?: Yes. Rallies tracks PCRX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is PCRX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for PCRX. It does not provide personalized investment advice.